Miles Carroll
Professor of Emerging Viruses
HOST-PATHOGEN INTERACTIONS OF HIGH CONSEQUENCE EMERGING VIRUSES
Our work centres around high consequence emerging viral infections. Currently, our focus is on Ebola, Lassa fever and SARS-CoV-2. We are interested in host-pathogen interactions, development of anti-virals and recently we have been looking at the IgG response following SARS-CoV-2 infection and/or vaccination in humans and animal models. To further support this work we are using a live virus neutralisation, multiplex immunoassays and novel ACE2 inhibition assay to inform on the ability of serum to neutralise SARS-CoV-2 variants of concern (VOC). We are also interested in the innate response to viral infection, particularly activation and/or evasion of the complement system
Recent publications
Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults-A Pilot Study.
Journal article
Alsaleh G. et al, (2026), Aging Cell, 25
Cephalosporins are potent SARS-CoV-2 main protease inhibitors.
Journal article
Muntean D-G. et al, (2026), Eur J Med Chem, 316
ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation.
Journal article
Tipton T. et al, (2026), Vaccine, 72
Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection.
Journal article
Clayton E. et al, (2026), J Gen Virol, 107
Current knowledge on the host-pathogen interactions of henipaviruses and novel platforms to enable further characterisation.
Journal article
Hantabal J. et al, (2026), EBioMedicine, 123